AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets
Rhea-AI Summary
AtaiBeckley (NASDAQ: ATAI), a clinical-stage mental health biotech, will be added to the Russell 2000 and Russell 3000 indexes at the U.S. market open on June 29, 2026, as part of the first 2026 Russell reconstitution.
Approximately $12.2 trillion is benchmarked to Russell U.S. indexes. The addition follows AtaiBeckley’s recent inclusion in the S&P Total Market, S&P Completion, and CRSP U.S. benchmark indexes, further broadening its visibility across major U.S. equity benchmarks.
Positive
- Addition to Russell 2000 and Russell 3000 effective June 29, 2026
- Exposure to index family benchmarking approximately $12.2 trillion in assets
- Follows inclusion in S&P Total Market, S&P Completion and CRSP U.S. indexes
- Index membership may broaden visibility with U.S. institutional and index-tracking investors
Negative
- None.
News Market Reaction – ATAI
In the Jun 25 session, ATAI gained 9.83%, reflecting a notable positive market reaction. Argus tracked a peak move of +22.0% during that session. Our momentum scanner triggered 55 alerts that day, indicating high trading interest and price volatility. Trading volume was elevated at 2.9x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 28 | Grant program launch | Positive | +2.1% | Launch of Patient Impact Grant Program supporting mental health non‑profits. |
| May 27 | Investor conferences | Neutral | +0.7% | Announcement of participation in multiple June investor conferences and webcasts. |
| May 12 | Earnings and pipeline | Neutral | +2.7% | Q1 2026 financials with cash runway and late‑stage pipeline timing update. |
| Apr 27 | Patient award recognition | Positive | -6.3% | Silver Award in 2026 Patient Participant Index for participant‑informed research. |
| Apr 08 | Clinical data update | Positive | -0.8% | Publication of BPL‑003 Phase 2a data showing rapid, durable antidepressant response. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent ATAI news has usually led to single‑digit price moves, with occasional negative reactions to otherwise constructive updates.
Key Terms
russell 2000® index financial
russell 3000® index financial
crsp® u.s. benchmark indexes financial
phase 3 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- AtaiBeckley to be added to the Russell 2000® Index and the broad-market Russell 3000® Index as part of 2026 reconstitution
- The Russell U.S. Indexes have approximately
$12.2 trillion in assets benchmarked - Inclusion expands AtaiBeckley’s visibility across U.S. equity markets following recent additions to the S&P Total Market Index, S&P Completion Index, and CRSP® U.S. benchmark indexes in March 2026
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will be added to the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. markets on June 29th as part of the first 2026 Russell indexes reconstitution.
Approximately
Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, said: “Joining the Russell Indexes - which collectively benchmark approximately
The addition follows AtaiBeckley’s recent inclusion in the S&P Total Market Index, S&P Completion Index, and CRSP® U.S. benchmark indexes, which expanded the Company’s visibility across major U.S. equity benchmarks.
About AtaiBeckley Inc.
AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 was granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration and is in Phase 3 clinical development; VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems.
For the latest updates and to learn more about the AtaiBeckley mission, visit www.ataibeckley.com or follow the Company on LinkedIn and on X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “anticipate,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: our business strategy and plans; the expected impact of the inclusion on the indices; the potential, success, cost and timing of development of our product candidates, including the progress of preclinical and clinical trials and related milestones; and the plans and objectives of management for future operations, research and development and capital expenditures.
Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in our quarterly reports and other filings with the SEC. AtaiBeckley disclaims any obligation to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.
Contact Information:
Investors:
Jason Awe, PhD
VP, Investor Relations
IR@ataibeckley.com
Media:
Charlotte Chorley
Associate Director, Communications
PR@ataibeckley.com
